



**Aimmune, a clinical-stage biopharmaceutical company, is developing desensitization treatments for people with food allergies. We aim to help protect patients by reducing the risk of life-threatening reactions due to accidental exposure to food allergens.**



### Working to Address an Unmet Need in Food Allergy

- Food allergy is a disease in which exposure to a food triggers a harmful immune response, such as anaphylaxis, which can be life-threatening.<sup>1</sup>
- More than 15 million Americans<sup>1-3</sup> and more than 17 million Europeans<sup>4</sup> have food allergies. In the U.S. alone, more than 1.7 million children are believed to have a peanut allergy.<sup>2,5</sup>
- Eight major food allergens – milk, egg, peanut, tree nuts, wheat, soy, fish and shellfish – are responsible for most of the serious food allergy reactions in the U.S.<sup>1</sup>
- Allergies to peanut, tree nuts, fish and shellfish are generally lifelong.<sup>1</sup>
- Food allergies are currently managed through strict avoidance of food allergens and early recognition and treatment of allergic reactions.<sup>6</sup>
- Even trace amounts of a food allergen can cause a reaction.<sup>7-12</sup> Each year in the U.S., 200,000 people require emergency medical care for allergic reactions to food.<sup>13</sup>



### MISSION

To improve the lives of people with food allergies

### TICKER

AIMT (Nasdaq)

### MANAGEMENT

**Jayson Dallas, MD**  
Chief Executive Officer

**Daniel Adelman, MD**  
Chief Medical Officer

**Sue Barrowcliffe**  
General Manager, Europe

**Eric Bjerkholt**  
Chief Financial Officer

**Becki Filice**  
SVP, Product and Portfolio Management

**Mary Rozenman, PhD**  
SVP, Corporate Development and Strategy

**Douglas Sheehy**  
General Counsel and Secretary

**William Turner**  
SVP, Global Regulatory Affairs and Quality Assurance

### CODIT™: Our Investigational Approach to Treating Food Allergies

- Our CODIT (Characterized Oral Desensitization ImmunoTherapy) approach is intended to be an optimized approach to food allergy treatment.
- The CODIT protocol involves gradual, controlled up-dosing followed by ongoing, low-dose maintenance.
- Our CODIT approach is intended to support food allergy products under development.



| PROGRAM        | PRE-IND   | PHASE 1/2* | PHASE 3 | APPROVED |
|----------------|---|------------|---------|----------|
| AR101 (PEANUT) | [Progress bar spanning Pre-Ind, Phase 1/2, and Phase 3] |            |         |          |
| AR201 (EGG)    | [Progress bar spanning Pre-Ind and Phase 1/2]           |            |         |          |
| AR301 (WALNUT) | [Progress bar in Pre-Ind]                               |            |         |          |

### First Application of CODIT: AR101, an Investigational Drug for Peanut Allergy

- AR101 is Aimmune's investigational characterized, oral biologic drug maintaining the protein profile found in peanuts.
- Fast Track Designation, and Breakthrough Designation in the 4-17 age group, allow for expedited FDA review.
- Pivotal Phase 3 clinical trial PALISADE enrolled more than 550 peanut-allergic participants ages 4-55 in the U.S., Canada and Europe; top-line data reported in February 2018.



**U.S. HEADQUARTERS**  
Brisbane, CA

**EUROPE HEADQUARTERS**  
London, U.K.

---

## References:

1. National Institute of Allergy and Infectious Diseases, National Institutes of Health. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Report of the NIAID-Sponsored Expert Panel. 2010. Retrieved from [www.niaid.nih.gov/topics/foodallergy/research/pages/reportfoodallergy.aspx](http://www.niaid.nih.gov/topics/foodallergy/research/pages/reportfoodallergy.aspx).
2. United States Census Bureau Quick Facts (2015 estimates).
3. Gupta RS, Springston EE, Warrier MR, et al. The Prevalence, Severity, and Distribution of Childhood Food Allergy in the United States. *Pediatrics*. 2011;128(1):e9-17.
4. EAACI. Food Allergy & Anaphylaxis Public Declaration. <http://www.eaaci.org/attachments/FoodAllergy&AnaphylaxisPublicDeclaration.pdf>. Updated February 11, 2015. Accessed December 4, 2017.
5. Gupta R, Warren C, Blumenstock J, et al. OR078 The Prevalence of Childhood Food Allergy in the United States: An Update. *Ann Allergy Asthma Immunol*. 2017;119(5 Suppl):S11.
6. U.S. Food and Drug Administration. Food allergies: What you need to know. 2017. Retrieved from <https://www.fda.gov/food/ingredientspackaginglabeling/foodallergens/ucm079311.htm>.
7. Hefle SL, Taylor SL. Allergenicity of edible oils. *Food Technol*. 1999; 53:62-70.
8. Laoprasert N, Wallen ND, Jones RT, et al. Anaphylaxis in a milk-allergic child following ingestion of lemon sorbet containing trace quantities of milk. *J Food Prot*. 1998;61:1522-1524.
9. Gern JE, Yang E, Evrard HM, Sampson HA. Allergic reactions to milk-contaminated nondairy products. *N Engl J Med*. 1991; 324:976-979.
10. Yunginger JW, Gauerke MB, Jones RT, et al. Use of radioimmunoassay to determine the nature, quantity and source of allergenic contamination of sunflower butter. *J Food Prot*. 1983; 46:625-628.
11. Jones R, Squillace D, Yunginger J. Anaphylaxis in a milk-allergic child after ingestion of milk contaminated kosher-pareve-labeled "dairy-free" dessert. *Ann Allergy*. 1992; 68:223-227.
12. Hourihane J, Kilbrun S, Nordlee J, et al. An evaluation of the sensitivity of subjects with peanut allergy to very low doses of peanut: a randomized, double-blind, placebo-controlled food challenge study. *J Allergy Clin Immunol*. 1997; 100:596-600.
13. Clark S, Espinola J, Rudders SA, Banerji, A, Camargo CA. Frequency of US emergency department visits for food-related acute allergic reactions. *J Allergy Clin Immunol*. 2011; 127(3):682-683.